Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 16;39(6):2806–2819. doi: 10.1007/s12325-022-02132-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Fig. 1 — COAST-V/W and COAST-X ASAS40 (ITT, NRI). Patients initially randomised to PBO in COAST-V/W switched to IXEQ2W or Q4W at week 16 by study design; PBO data are summarised up to week 16. Data displayed as mean. Significantly greater response rate versus PBO following IXE treatment denoted by * (p ≤ 0.05), ** (p ≤ 0.01), *** (p ≤ 0.001). ASAS40 Assessment in SpondyloArthritis International Society 40%, Q4W every 4 weeks, Q2W every 2 weeks, ITT intent-to-treat population, NRI non-responder imputation, PBO placebo, IXE ixekizumab